Classifications: anticoagulant; antiplatelet agent; glycoprotein iib/iiia receptor inhibitor;
Therapeutic: antiplatelet

Prototype: Abciximab
Pregnancy Category: B


250 mcg/mL, 50 mcg/mL injection


Antiplatelet agent that binds to the glycoprotein IIb/IIIa receptor of platelets inhibiting platelet aggregation.

Therapeutic Effect

Effectiveness indicated by minimizing thrombotic events during treatment of acute coronary syndrome.


Acute coronary syndromes (unstable angina, MI).


Active internal bleeding within 30 d; acute pericarditis; aortic dissection; intracranial aneurysm, intracranial mass, coagulopathy; concurrent use with another glycoprotein IIb/IIIa receptor inhibitor (e.g., eptifibatide, abciximab), or heparin; history of aneurysm or AV malformation; history of intracranial hemorrhage or neoplasm; hypersensitivity to tirofiban; active abnormal bleeding; retinal bleeding; hemorrhagic retinopathy; major surgery or trauma within 3 d; stroke within 30 d; history of hemorrhagic stroke; thrombocytopenia following administration of tirofiban; within 4 h of percutaneous coronary intervention (PCI); lactation.

Cautious Use

Concomitant use with thrombolytic agents or drugs that cause hemolysis; platelet count <150,000 mm3; severe renal insufficiency; pregnancy (category B). Safety and efficacy in children <18 y are unknown.

Route & Dosage

Acute Coronary Syndromes
Adult: IV 0.4 mcg/kg/min for 30 min, then 0.1 mcg/kg/min for 12–24 h after angioplasty or arteriectomy

Renal Impairment
Clcr <30 mL/min: reduce rate of infusion 50%



PREPARE: IV Infusion: Withdraw 100 mL from a 500-mL bag of NS or D5W and replace with 100 mL of tirofiban HCl injection. If a 250-mL IV bag is used, withdraw 50 mL of IV solution and replace with 50 mL of tirofiban injection. Either preparation yields 50 mcg/mL. Mix well before infusing. Note: Commercially premixed IV tirofiban solutions are available.  

ADMINISTER: IV Infusion: An initial loading dose of 0.4 mcg/kg/min for 30 min is usually followed by a maintenance infusion of 0.1 mcg/kg/min.  

INCOMPATIBILITIES Y-site: Diazepam, tenecteplase.

  • Discard unused IV solution 24 h following start of infusion.
  • Store unopened containers at 15°–30° C (59°–86° F). Do not freeze and protect from light.

Adverse Effects (≥1%)

Body as a Whole: Edema, swelling, pelvic pain, vasovagal reaction, leg pain. CNS: Dizziness. CV: Bradycardia, coronary artery dissection. GI: GI bleeding. Hematologic: Bleeding (major bleeding), anemia, thrombocytopenia. Skin: Sweating.


Drug: Increased risk of bleeding with anticoagulants, nsaids, salicylates, antiplatelet agents. Herbal: Feverfew, garlic, ginger, ginkgo, horse chestnut may increase risk of bleeding.


Duration: 4–8 h after stopping infusion. Distribution: 65% protein bound. Metabolism: Minimally metabolized. Elimination: 65% in urine, 25% in feces. Half-Life: 2 h.

Nursing Implications

Assessment & Drug Effects

  • Lab tests: Monitor platelet count, Hgb and Hct before treatment, (within 6 h of infusing loading dose), and frequently throughout treatment; monitor aPTT and ACT.
  • Withhold drug and notify physician if thrombocytopenia (platelets <100,000) is confirmed.
  • Monitor carefully for and immediately report S&S of internal or external bleeding.
  • Wait at least 3–4 h after heparin is stopped and until ACT <180 sec and aPPT <45 sec before removing the femoral catheter sheath.
  • Minimize unnecessary invasive procedures and devices to reduce the risk of bleeding.

Patient & Family Education

  • Report unexplained pelvic or abdominal pain.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

© 2006-2022 medpill.info Last Updated On: 11/16/2022 (0)
Wait 20 seconds...!!!